NCI-H596 In Vivo Anti-Tumor Efficacy Assay

This assay is to provide NCI-H596-based In Vivo Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

NCI-H596

Human

The NCI-H596 cell line was derived by A.F. Gazdar and H. Oie in 1983 from a tumor mass in the chest wall of a patient with adenosquamous carcinoma of the lung. The specimen was obtained prior to therapy.

Adenosquamous Carcinoma

Oncology

In Vivo Anti-Tumor Efficacy Assay

After positive anti-tumor efficacy data is concluded using in vitro assays, we can start to initiate in vivo anti-tumor efficacy studies. Creative Biolabs offers a wide variety of PDX or CDX models to facilitate the efficacy studies. This assy will be used to evaluate the anti-tumor efficacy of your therapeutic candidates, such as small molecules, antibodies, CARTs or other biologics. Detailed group set up and other plans will be discussed according to your specific requirements.

Oncology In Vivo Assays